Early eculizumab treatment improves renal outcomes in pediatric lupus nephritis with thrombotic microangiopathy
In pediatric LN with TMA, eculizumab outperforms conventional therapy by accelerating renal recovery. Early use-after excluding TTP, infections, and drug-related causes-may mitigate renal damage and improve outcomes. Given that this is a retrospective study with a small sample size, the findings require validation from larger-scale clinical studies.
Authors
- Weijie Kang
- Shihan Yu
- Youying Mao
- Jia He (ORCID: https://orcid.org/0000-0001-6153-9550)
- Zhengyu Zhou
- Wei Zhou
- Lei Yin
- Jiayao Shen
- Chenxing Zhang
- Jie Zhang
Institutions
- Shanghai Medical College of Fudan University (CN)
- Shanghai Children's Medical Center (CN)
- Tongren Hospital (CN)
- Songjiang District Central Hospital (CN)
Publication Details
- Journal
- Nephrology Dialysis Transplantation
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1093/ndt/gfag031
- Primary Topic
- Complement system in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00